Toxicity associated with tuberculosis chemotherapy in the REMoxTB study-Reference-Cited by-同舟云学术

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

Published:2018-07-11 Issue:1 Volume:18 Page:
ISSN:1471-2334
Container-title:BMC Infectious Diseases
language:en
Short-container-title:BMC Infect Dis

Author:

Tweed Conor D.^ORCID,Crook Angela M.,Amukoye Evans I.,Dawson Rodney,Diacon Andreas H.,Hanekom Madeline,McHugh Timothy D.,Mendel Carl M.,Meredith Sarah K.,Murphy Michael E.,Murthy Saraswathi E.,Nunn Andrew J.,Phillips Patrick P. J.,Singh Kasha P.,Spigelman Melvin,Wills Genevieve H.,Gillespie Stephen H.

Funder

Bill & Melinda Gates Foundation

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Link

http://link.springer.com/content/pdf/10.1186/s12879-018-3230-6.pdf

Reference42 articles.

1. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb J a, Nolan CM, et al. an official ATS Statement : hepatotoxicity of Antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935–52.

2. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9:2026–30.

3. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line Antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472–7.